Navigation Links
Vivakor Announces Mechanics of Dividend Distribution
Date:12/8/2009

CORALVILLE, Iowa, Dec. 8 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the mechanics for how shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date will be December 9, 2009, and will be conducted as an "upon surrender" distribution. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. The shares of Health America being distributed shall be recorded in the name of each Vivakor shareholder of record on December 1, 2009 as a journal entry with the transfer agent, Integrity Stock Transfer, located in Las Vegas, Nevada. Any shareholder of Vivakor as of the record date, December 1, 2009, may request a certificate directly from the transfer agent, or may simply request a confirmation that a journal entry of the shares with the transfer agent. No other action is required by the Vivakor shareholders to obtain their shares.

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

About HealthAmerica, Inc.

HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM)) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.

At the end of 2000, there were approximately 9,500 MRI (magnetic resonance imaging) systems installed worldwide. While changes in medical reimbursements have slowed the sale of new machines, there is an increased demand for improved efficiency (i.e. accelerated patient throughput) from current systems. Additionally, intense competition between various medical facilities and the rapid distribution of new advances in imaging (such as MR angiographies, which allow evaluation of blood vessels without any invasive procedure) puts additional pressure on MRI because increased image quality requires additional time. Thus there is a huge need for an application like VIVASlices that can improve both throughput and image quality.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's and HealthAmerica's products and markets. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.



    Contact:
    Vivakor, Inc.
    Matt Nicosia, 319-625-2172
    mnicosia@vivakor.com


SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
2. Vivakor Confirms Record Date of Stock Dividend
3. Vivakor, Inc. Announces Stock Dividend
4. The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program
5. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
6. ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
9. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
10. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
11. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):